Tasly Pharmaceutical Group Co (SHSE:600535) Net Change in Cash : ¥-1,513 Mil (TTM As of Mar. 2025)

View and export this data going back to 2002. Start your Free Trial

What is Tasly Pharmaceutical Group Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Tasly Pharmaceutical Group Co's Net Change in Cash for the three months ended in Mar. 2025 was ¥-78 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-1,513 Mil.

Tasly Pharmaceutical Group Co Net Change in Cash Historical Data

The historical data trend for Tasly Pharmaceutical Group Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tasly Pharmaceutical Group Co Net Change in Cash Chart

Tasly Pharmaceutical Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

334.16

276.97

807.37

-730.54

-1,380.05

Tasly Pharmaceutical Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															54.66	-279.77	-951.66	-203.28	-78.33

Tasly Pharmaceutical Group Co Net Change in Cash Calculation

Tasly Pharmaceutical Group Co's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	2014.559	+	-940.875	+	-2453.892	+	0.159
	=	-1,380

Tasly Pharmaceutical Group Co's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -362.37 + -48.077 + 332.276 + -0.155

= -78

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,513 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tasly Pharmaceutical Group Co Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Tasly Pharmaceutical Group Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Tasly Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tasly Pharmaceutical Group Co Ltd (SHSE:600535) » Definitions » Net Change in Cash

Comparable Companies

SHSE:600521 SZSE:002603 SZSE:002262 SZSE:300558 SHSE:600566 SHSE:600329 SZSE:002773 SHSE:600380 SHSE:600062 SZSE:000623 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA

Traded in Other Exchanges

N/A

Address

2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410

Website

http://www.tasly.com

Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.

Executives

Wu Nai Feng Director

Tasly Pharmaceutical Group Co Headlines

No Headlines